Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib maintenance after definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma
ChiCTR2100053579Phase 4Recruiting
- Sponsor
- Renmin Hospital, Hubei University of Medicine
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Renmin Hospital, Hubei University of Medicine. Primary endpoint: Progression free survival. Started Dec 2021; status: recruiting.
02
Drugs
anlotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100053579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053579.